Homology Medicines (DB:35H) - Aandelenkoers, Nieuws & Analyse

35H Overzicht aandelen

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States.

Over het bedrijf

35H fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 13.23% per jaar groeien

Risicoanalyse

Heeft minder dan 1 jaar cash runway

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen betekenisvolle marktkapitalisatie ( €54M )

+ 1 meer risico

Homology Medicines, Inc. Concurrenten

Medigene

XTRA:MDG1

€24.2m

Heidelberg Pharma

XTRA:HPHA

€116.5m

2invest

XTRA:2INV

€59.2m

co.don

XTRA:CNW

€6.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Homology Medicines
Historische aandelenkoersen
Huidige aandelenkoers	US$0.83
52 Week Hoogtepunt	US$1.26
52 Week Laag	US$0.31
Bèta	-0.11
11 maand verandering	5.06%
3 maanden verandering	73.64%
1 Jaar Verandering	4.98%
33 jaar verandering	-89.49%
5 jaar verandering	-96.65%
Verandering sinds IPO	-94.20%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	35H	DE Biotechs	DE Markt
7D	3.8%	-3.1%	-1.0%
1Y	5.0%	-15.2%	16.1%

Rendement versus industrie: 35H presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -15.2 % opleverde.

Rendement versus markt: 35H presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 16.1 % opleverde.

Prijsvolatiliteit

Is 35H's price volatile compared to industry and market?
35H volatility
35H Average Weekly Movement	14.2%
Biotechs Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.5%

Stabiele aandelenkoers: De aandelenkoers van 35H is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 14% ) van 35H is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	7	n/a	www.homologymedicines.com

Homology Medicines, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Homology Medicines zich tot de beurswaarde?
35H fundamentele statistieken
Marktkapitalisatie	€49.80m
Inkomsten(TTM)	-€104.32m
Inkomsten(TTM)	€1.07m

46.6x

P/S-verhouding

-0.5x

Koers/Winstverhouding

Is 35H overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
35H resultatenrekening (TTM)
Inkomsten	US$1.16m
Kosten van inkomsten	US$62.00m
Brutowinst	-US$60.85m
Overige uitgaven	US$52.12m
Inkomsten	-US$112.96m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.94
Brutomarge	-5,263.49%
Nettowinstmarge	-9,771.71%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 35H op de lange termijn?

Bekijk historische prestaties en vergelijking

35H Overzicht aandelen

Beloningen

Risicoanalyse

Homology Medicines, Inc. Concurrenten

XTRA:MDG1

€24.2m

XTRA:HPHA

€116.5m

XTRA:2INV

€59.2m

XTRA:CNW

€6.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index

Full year 2023 earnings released: US$1.95 loss per share (vs US$0.087 loss in FY 2022)

Insufficient new directors

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Recent updates

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index

Full year 2023 earnings released: US$1.95 loss per share (vs US$0.087 loss in FY 2022)

Insufficient new directors

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Third quarter 2023 earnings released: US$0.57 loss per share (vs US$0.59 loss in 3Q 2022)

Homology Medicines, Inc. Approves Reduction in Workforce

New major risk - Share price stability

New major risk - Revenue and earnings growth

Homology Medicines Announces First Data from IND-Enabling Studies with GTx-Mab Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, At the ASGCT Annual Meeting

First quarter 2023 earnings released: US$0.50 loss per share (vs US$1.61 profit in 1Q 2022)

Full year 2022 earnings released: US$0.087 loss per share (vs US$1.73 loss in FY 2021)

No longer forecast to breakeven

Homology Medicines, Inc. Provides Update on pheEDIT and juMPStart Clinical Trials

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$0.54 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$0.54 loss in 3Q 2021)

Insufficient new directors

Homology Medicines, Inc. Appoints Albert Seymour as Chief Executive Officer

Forecast to breakeven in 2022

Homology Medicines Announces Optimized, in Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2000 Dynamic Index

Homology Medicines, Inc. Announces FDA Lifted Clinical Hold on Phenix Gene Therapy Trial for Pku

First quarter 2022 earnings released: EPS: US$1.61 (vs US$0.021 loss in 1Q 2021)

Robbins Geller Rudman & Dowd LLP Announces That Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Homology Medicines, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Homology Medicines, Inc. Announces Promotion of Albert Seymour to President

Homology Medicines, Inc. Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU

Homology Medicines Announces Multiple Presentations on HMI-203 Gene Therapy Candidate for the Treatment of Hunter Syndrome

Insufficient new directors

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.62 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.54 loss per share (vs US$0.78 loss in 2Q 2020)

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2500 Growth Index

Homology Medicines, Inc. Announces Presentations on Its Expanding Genetic Medicines Platform and Internal GMP Manufacturing

First quarter 2021 earnings released: US$0.021 loss per share (vs US$0.78 loss in 1Q 2020)

Full year 2020 earnings released: US$2.80 loss per share (vs US$2.47 loss in FY 2019)

Revenue misses expectations

Novartis Elects to Terminate the Collaboration and License Agreement with Homology Medicines, Inc

New 90-day high: €12.09

New 90-day high: €10.86

Homology Medicines, Inc. Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (Pku) and Hunter Syndrome (Mps Ii)

New 90-day low: €7.86

New 90-day low: €8.14

Third quarter 2020 earnings released: US$0.62 loss per share

Revenue beats expectations

Homology Medicines, Inc. announced that it expects to receive $60 million in funding from Pfizer Inc.

Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from S&P Biotechnology Select Industry Index

New 90-day low - €8.36

New 90-day low - €8.97

First half earnings released

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Homology Medicines, Inc. Samenvatting

46.6x

-0.5x

Inkomsten en omzet